Patent Granted Does Not Mean Freedom to Operate
A granted patent protects your claims. It does not guarantee you can commercialise without infringing third party rights. Patentability and Freedom to Operate are legally distinct.
One of the most persistent misconceptions in deep tech is this:
“If the patent office granted our patent, we must have Freedom to Operate.”
That is legally incorrect.
A patent and Freedom to Operate answer two completely different questions.
What Freedom to Operate actually means
Freedom to Operate asks:
Can we manufacture, use, sell, or import this specific product, in this specific territory, at this specific time, without infringing third party patents?
It is an infringement risk assessment.
It analyses:
- Active claims owned by others
- Geographic scope
- Legal status of relevant patents
- How your actual product maps against those claims
It measures litigation exposure.
It measures whether someone can block you.
What an IP strategy actually covers
IP strategy answers a different question:
How do we protect and leverage our intangible assets to secure competitive advantage?
It includes:
- Filing roadmap
- Territorial coverage
- Trade secret allocation
- Ownership structure
- Licensing logic
- Enforcement planning
It is about value capture and defensibility.
It is not an infringement clearance analysis.
The critical legal distinction
Patent offices do not assess Freedom to Operate.
Examiners evaluate:
- Novelty
- Inventive step
- Industrial applicability
- Formal requirements
They do not determine whether commercialising your product infringes third party rights.
Patentability and infringement are legally distinct.
You can own a granted patent and still be unable to commercialise because:
- Your invention improves a broader patented technology
- Your product integrates patented subsystems
- A blocking patent sits upstream in the value chain
A patent gives you the right to exclude others within the scope of your claims.
It does not give you permission to operate.
Why this matters in EU funding
For EU funding applicants and serious scale ups, this distinction is not theoretical.
Evaluators expect to see two separate elements:
- A coherent IP strategy
- A credible Freedom to Operate status
That means:
- A clearly defined product configuration
- Defined target territories
- Identified third party risks
- A mitigation plan such as design around, licensing, or staged market entry
Writing “we have a granted patent” is not evidence of commercial readiness.
Protection and permission are not the same thing.
Patent strength and absence of infringement risk are not the same thing.
Patent granted does not equal Freedom to Operate.
Treating them as equivalent is not a minor misunderstanding.
It is a strategic error.
Better to identify this gap before submission than inside the ESR.
Run an evaluator grade review on the draft
Upload a version, select programme context, and get structured feedback you can act on.